Vaccine Stocks List

Compare vaccine stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

NASDAQ:GILD NASDAQ:MRNA NASDAQ:NVAX NYSE:JNJ NYSE:PFE

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$81.39 -3.1%	$85.87	$57.17 ▼ $89.74	$102.08B	0.39	6.53 million shs	10.76 million shs
MRNA Moderna	$176.35 +1.2%	$186.42	$115.03 ▼ $217.25	$67.75B	1.65	3.89 million shs	4.03 million shs
NVAX Novavax	$12.01 +6.9%	$12.68	$8.75 ▼ $101.39	$942.79M	1.73	7.39 million shs	9.55 million shs
JNJ Johnson & Johnson	$165.54 +0.4%	$174.84	$155.72 ▼ $186.69	$432.80B	0.54	8.20 million shs	10.06 million shs
PFE Pfizer	$44.34 +0.8%	$49.16	$41.44 ▼ $56.32	$248.89B	0.63	26.47 million shs	35.16 million shs

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	-3.11%	-2.67%	-4.68%	+1.31%	+23.66%
MRNA Moderna	+1.18%	-8.74%	-1.47%	+11.33%	+3.97%
NVAX Novavax	+6.95%	+9.38%	+22.68%	-38.09%	-86.57%
JNJ Johnson & Johnson	+0.38%	-1.98%	-7.10%	-3.46%	-4.18%
PFE Pfizer	+0.84%	+0.20%	-13.50%	-6.10%	-17.68%

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GILD Gilead Sciences	2.954 of 5 stars	2.2	5.0	2.5	4.1	3.7	2.5	2.5
MRNA Moderna	2.1963 of 5 stars	2.3	3.0	0.0	4.6	1.8	3.3	1.3
NVAX Novavax	1.9005 of 5 stars	3.1	1.0	0.0	4.7	1.8	0.8	0.6
JNJ Johnson & Johnson	3.252 of 5 stars	3.2	5.0	4.2	3.9	3.5	2.5	1.9
PFE Pfizer	3.4681 of 5 stars	3.2	5.0	5.0	4.5	2.8	1.7	3.1

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.47	Hold	$87.40	7.38% Upside
MRNA Moderna	2.45	Hold	$192.00	8.87% Upside
NVAX Novavax	2.29	Hold	$92.50	670.19% Upside
JNJ Johnson & Johnson	2.46	Hold	$185.23	11.89% Upside
PFE Pfizer	2.33	Hold	$52.13	17.58% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
2/1/2023	JNJ Johnson & Johnson	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$215.00
2/1/2023	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00
2/1/2023	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight	$53.00 ➝ $45.00
2/1/2023	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$75.00
2/1/2023	PFE Pfizer	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform	$49.00 ➝ $48.00
2/1/2023	PFE Pfizer	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral	$50.00 ➝ $46.00
2/1/2023	PFE Pfizer	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $53.00
2/1/2023	PFE Pfizer	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform	$54.00 ➝ $50.00
2/1/2023	PFE Pfizer	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight	$49.00 ➝ $44.00
1/31/2023	PFE Pfizer	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$50.00
1/26/2023	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$55.00 ➝ $47.00

(Data available from 2/2/2020 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$27.31B	3.74	$8.69 per share	9.37	$16.79 per share	4.85
MRNA Moderna	$18.47B	3.67	$30.83 per share	5.72	$34.89 per share	5.05
NVAX Novavax	$1.15B	0.82	N/A	N/A	($4.65) per share	-2.58
JNJ Johnson & Johnson	$94.94B	4.56	$12.92 per share	12.81	$28.12 per share	5.89
PFE Pfizer	$100.33B	2.48	$7.39 per share	6.00	$13.80 per share	3.21

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$6.23B	$2.65	30.71	12.02	0.81	12.29%	38.51%	12.35%	2/2/2023 (Confirmed)
MRNA Moderna	$12.20B	$27.64	6.38	150.73	N/A	55.00%	70.03%	45.09%	2/23/2023 (Estimated)
NVAX Novavax	-$1.74B	-$17.30	N/A	N/A	N/A	-71.59%	N/A	-51.33%	2/27/2023 (Estimated)
JNJ Johnson & Johnson	$17.94B	$6.74	24.56	15.17	2.81	18.90%	35.94%	15.27%	4/18/2023 (Estimated)
PFE Pfizer	$21.98B	$5.48	8.09	10.38	1.46	31.27%	43.02%	19.70%	5/2/2023 (Estimated)

Latest Vaccine Stocks Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/2/2023	N/A	GILD Gilead Sciences	$1.49	$1.67	+$0.18	N/A	$6.63 billion	$7.39 billion
1/31/2023	Q4 2022	PFE Pfizer	$1.03	$1.14	+$0.11	$1.41	$24.40 billion	$24.30 billion
1/24/2023	Q4 22	JNJ Johnson & Johnson	$2.22	$2.35	+$0.13	$3.37	$23.90 billion	$23.71 billion
11/8/2022	Q3 2022	NVAX Novavax	$2.21	-$2.15	-$4.36	-$2.15	$555.50 million	$734.58 million
11/3/2022	Q3 2022	MRNA Moderna	$3.04	$2.53	-$0.51	$2.53	$3.33 billion	$3.36 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$2.92	3.59%	+5.03%	110.19%	7 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.52	2.73%	+5.87%	67.06%	61 Years
PFE Pfizer	$1.64	3.70%	+3.31%	29.93%	12 Years

Latest Vaccine Stocks Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/3/2023	JNJ Johnson & Johnson	Quarterly	$1.13	2.54%	2/17/2023	2/21/2023	3/7/2023
12/9/2022	PFE Pfizer	quarterly	$0.41	3.16%	1/26/2023	1/27/2023	3/3/2023

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	1.14	1.30	1.16
MRNA Moderna	0.05	2.10	1.80
NVAX Novavax	N/A	1.06	1.01
JNJ Johnson & Johnson	0.37	1.43	1.18
PFE Pfizer	0.35	1.59	1.37

Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	78.72%
MRNA Moderna	63.11%
NVAX Novavax	45.7%
JNJ Johnson & Johnson	67.94%
PFE Pfizer	67.62%

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.16%
MRNA Moderna	17.3%
NVAX Novavax	2.1%
JNJ Johnson & Johnson	0.35%
PFE Pfizer	0.05%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	14,400	1.25 billion	1.25 billion	Optionable
MRNA Moderna	2,700	384.18 million	317.72 million	Optionable
NVAX Novavax	1,541	78.50 million	76.86 million	Optionable
JNJ Johnson & Johnson	141,700	2.61 billion	2.61 billion	Optionable
PFE Pfizer	79,000	5.61 billion	5.61 billion	Optionable

Vaccine Stocks Headlines

Source	Headline
	Pfizer Inc. (NYSE:PFE) Given Average Rating of "Hold" by Brokerages marketbeat.com - February 3 at 1:26 AM
	Pfizer (PFE) Q4 earnings 2022 - CNBC news.google.com - February 2 at 6:47 PM
	Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales finance.yahoo.com - February 2 at 6:47 PM
	COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst finance.yahoo.com - February 2 at 6:47 PM
	Cathie Woods' Ark Innovation ETF Set To Rebound in 2023? (PFE) marketbeat.com - February 2 at 1:50 PM
	Pfizer's former CFO says you should ask yourself these questions if you want to become a finance chief fortune.com - February 2 at 9:18 AM
	Pfizer (NYSE:PFE) Sees Strong Trading Volume After Strong Earnings americanbankingnews.com - February 2 at 9:02 AM
	Pfizer (PFE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance news.google.com - February 2 at 8:46 AM
	Pfizer Inc. (NYSE:PFE) Q4 2022 Earnings Call Transcript - Yahoo Finance news.google.com - February 2 at 8:46 AM
	The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion - CNBC news.google.com - February 2 at 8:46 AM
	Pfizer (NYSE:PFE) Price Target Cut to $48.00 by Analysts at SVB Leerink americanbankingnews.com - February 2 at 7:51 AM
	Pfizer (NYSE:PFE) Price Target Cut to $50.00 by Analysts at Credit Suisse Group americanbankingnews.com - February 2 at 7:51 AM
	Pfizer (NYSE:PFE) Earns "Overweight" Rating from Cantor Fitzgerald americanbankingnews.com - February 2 at 7:10 AM
	Pfizer (NYSE:PFE) Given New $44.00 Price Target at Barclays americanbankingnews.com - February 2 at 5:56 AM
	Pfizer (NYSE:PFE) PT Lowered to $45.00 at Morgan Stanley americanbankingnews.com - February 2 at 5:22 AM
	How much will Pfizer make from covid products in 2023 - Quartz news.google.com - February 2 at 1:11 AM
	Pfizer is expecting its covid windfall to end in 2023 finance.yahoo.com - February 1 at 8:10 PM
	Novavax Shares Jumped in January While Others Slipped (PFE) marketbeat.com - February 1 at 7:01 PM
	Pfizer Loses $43 Billion of Value in Worst Month Since 2009 - Bloomberg news.google.com - February 1 at 3:09 PM
	U.S. FDA removes COVID test requirements for Pfizer, Merck pills - Reuters news.google.com - February 1 at 3:09 PM
	What James Gunn had to say about Zachary Levi's Pfizer tweet - Los Angeles Times news.google.com - February 1 at 3:09 PM
	Company News for Feb 1, 2023 finance.yahoo.com - February 1 at 3:09 PM
	Video of Pfizer Employee Explaining COVID Vaccine Research ... - Medpage Today news.google.com - February 1 at 10:09 AM
	Pfizer sees COVID-19 product sales plummeting in 2023 - FiercePharma news.google.com - February 1 at 10:09 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences

NASDAQ:GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Moderna

NASDAQ:MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Novavax

NASDAQ:NVAX

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Johnson & Johnson

NYSE:JNJ

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer

NYSE:PFE

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial